MSH2 Gene Mismatch Repair Cancer Syndrome NGS Genetic DNA Test
Comprehensive Genetic Testing for Hereditary Cancer Risk
The MSH2 Gene Mismatch Repair Cancer Syndrome NGS Genetic DNA Test represents a breakthrough in personalized cancer risk assessment. This advanced genetic screening utilizes Next-Generation Sequencing (NGS) technology to detect mutations in the MSH2 gene, a crucial component of the DNA mismatch repair system. When this system malfunctions due to MSH2 mutations, it can lead to Lynch syndrome, significantly elevating cancer susceptibility throughout an individual’s lifetime.
What Does This Test Measure?
This sophisticated genetic analysis specifically targets the MSH2 gene located on chromosome 2p21. The test examines:
- Complete MSH2 gene sequencing for point mutations
- Detection of large deletions and duplications
- Assessment of splice site variants
- Identification of promoter region abnormalities
- Comprehensive analysis of all coding regions
The MSH2 protein functions as a critical DNA mismatch repair enzyme that corrects errors occurring during DNA replication. When mutations disrupt this repair mechanism, cells accumulate genetic errors at an accelerated rate, dramatically increasing cancer development risk.
Who Should Consider MSH2 Genetic Testing?
Clinical Indications and Risk Factors
This test is particularly recommended for individuals with:
- Personal history of colorectal cancer diagnosed before age 50
- Multiple primary Lynch syndrome-related cancers
- Endometrial cancer diagnosed before age 50
- Strong family history of colorectal, endometrial, gastric, ovarian, or urinary tract cancers
- First-degree relatives with known Lynch syndrome mutations
- Abnormal tumor testing showing microsatellite instability (MSI)
- Families meeting Amsterdam II criteria or revised Bethesda guidelines
- Unexplained early-onset cancers in multiple family members
Recognizing Potential Symptoms
While genetic testing focuses on predisposition rather than symptoms, individuals with potential Lynch syndrome may experience:
- Unexplained gastrointestinal symptoms at young ages
- Multiple polyps detected during colonoscopy
- Unexpected cancer diagnoses in young adulthood
- Family patterns of cancer across generations
- Rare cancer types appearing in family members
Benefits of MSH2 Genetic Testing
Proactive Health Management
Undergoing MSH2 genetic testing provides numerous advantages for comprehensive healthcare planning:
- Early Risk Identification: Detect genetic predisposition before cancer development
- Personalized Surveillance: Implement targeted cancer screening protocols
- Preventive Strategies: Develop customized prevention plans based on genetic risk
- Family Planning Guidance: Make informed reproductive decisions
- Family Member Screening: Identify at-risk relatives for proactive testing
- Treatment Optimization: Guide cancer treatment decisions when applicable
- Psychological Relief: Reduce uncertainty through definitive genetic information
- Cost-Effective Healthcare: Potentially reduce long-term medical expenses through prevention
Understanding Your Test Results
Interpreting Genetic Findings
Your MSH2 genetic test results will fall into one of several categories:
- Positive Result: A pathogenic mutation detected indicates Lynch syndrome diagnosis, requiring enhanced cancer surveillance and preventive measures
- Negative Result: No MSH2 mutation found, though other genetic factors may still contribute to cancer risk
- Variant of Uncertain Significance (VUS): A genetic change with unknown clinical significance requiring ongoing monitoring and family studies
- Benign Polymorphism: Common genetic variations not associated with increased cancer risk
All positive results should be discussed with a genetic counselor and healthcare provider to develop appropriate management strategies. Negative results in individuals with strong family histories may warrant consideration of testing for other Lynch syndrome genes or different hereditary cancer syndromes.
Test Details and Pricing
| Test Component | Details |
|---|---|
| Test Name | MSH2 Gene Mismatch Repair Cancer Syndrome NGS Genetic DNA Test |
| Regular Price | $700 USD |
| Discount Price | $500 USD |
| Turnaround Time | 3 to 4 Weeks |
| Sample Type | Blood, Extracted DNA, or One Drop Blood on FTA Card |
| Testing Method | Next-Generation Sequencing (NGS) Technology |
| Specialty | Oncology Genetics |
Pre-Test Requirements
Before undergoing testing, patients should provide:
- Complete clinical history relevant to cancer risk assessment
- Participation in genetic counseling session
- Detailed pedigree chart documenting family cancer history
- Information about affected family members with MSH2-related conditions
Nationwide Testing Availability
We proudly offer the MSH2 Gene Mismatch Repair Cancer Syndrome NGS Genetic DNA Test across our extensive network of testing facilities throughout the United States. Our services are available in all major metropolitan areas including New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, San Jose, and many more locations nationwide.
Take Control of Your Genetic Health Today
Don’t leave your cancer risk to chance. The MSH2 genetic test provides definitive information that can guide your healthcare decisions for years to come. With our discounted price of $500 USD (regularly $700 USD), comprehensive genetic testing is more accessible than ever.
Ready to schedule your test? Contact our genetic specialists today to discuss your testing options and begin the process of understanding your genetic cancer risk.
Call or WhatsApp: +1(267) 388-9828
Our team of genetic counselors and healthcare professionals is ready to assist you with scheduling, answer your questions about the testing process, and provide guidance on next steps based on your results. Take the first step toward personalized cancer prevention and early detection today.
